Involutional Osteoporosis
6
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
5
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Ono PharmaceuticalJapan - Osaka
3 programs3
Minodronic acid hydratePhase 31 trial
ONO-5920Phase 31 trial
ONO-5920Phase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Ono PharmaceuticalMinodronic acid hydrate
Ono PharmaceuticalONO-5920
Ono PharmaceuticalONO-5920
Clinical Trials (3)
Total enrollment: 1,344 patients across 3 trials
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
Start: Jun 2004444 patients
Phase 3Completed
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
Start: May 2003250 patients
Phase 3Completed
Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
Start: Aug 2002650 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
5 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.